Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $22.00.

Several equities research analysts have weighed in on the company. HC Wainwright raised Aura Biosciences to a "buy" rating and set a $22.00 price target for the company in a report on Wednesday, May 28th. Citigroup reissued an "outperform" rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, JMP Securities reissued a "market outperform" rating and issued a $19.00 price objective on shares of Aura Biosciences in a research note on Friday, May 23rd.

Insider Buying and Selling at Aura Biosciences

In related news, Director David Michael Johnson acquired 20,000 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was purchased at an average cost of $4.90 per share, with a total value of $98,000.00. Following the completion of the acquisition, the director directly owned 166,167 shares of the company's stock, valued at approximately $814,218.30. This trade represents a 13.68% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Anthony S. Gibney bought 50,000 shares of the company's stock in a transaction on Friday, May 16th. The shares were acquired at an average price of $4.90 per share, for a total transaction of $245,000.00. Following the completion of the acquisition, the insider owned 58,452 shares in the company, valued at $286,414.80. This represents a 591.58% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in shares of Aura Biosciences in the 4th quarter worth $50,000. GAMMA Investing LLC boosted its position in Aura Biosciences by 5,766.9% in the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock valued at $57,000 after buying an additional 9,573 shares during the last quarter. Ascent Group LLC acquired a new position in shares of Aura Biosciences in the first quarter worth about $124,000. ProShare Advisors LLC acquired a new position in shares of Aura Biosciences in the 4th quarter valued at approximately $127,000. Finally, Harvest Investment Services LLC bought a new stake in shares of Aura Biosciences in the 4th quarter worth about $133,000. Hedge funds and other institutional investors own 96.75% of the company's stock.

Aura Biosciences Stock Down 5.8%

Shares of AURA stock opened at $6.71 on Friday. The company has a market cap of $337.31 million, a P/E ratio of -3.53 and a beta of 0.45. Aura Biosciences has a twelve month low of $4.35 and a twelve month high of $12.38. The business has a fifty day simple moving average of $6.23 and a 200 day simple moving average of $6.67.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.08). As a group, equities research analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.